Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) Estimate, Sales $13.77M Beat $11.56M Estimate
Portfolio Pulse from Benzinga Newsdesk
Exagen (NASDAQ:XGN) reported Q4 GAAP EPS of $(0.31), surpassing the $(0.43) estimate, and sales of $13.77M, exceeding the $11.56M estimate. This represents a significant improvement over the previous year, with a 62.65% decrease in losses per share and a 7.23% increase in sales.
March 18, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exagen reported a significant beat on both EPS and sales estimates for Q4, showing substantial improvement over the previous year.
Exagen's better-than-expected quarterly results, with a notable beat on both EPS and sales estimates, indicate strong operational performance and financial health. This positive news is likely to instill investor confidence and could lead to a short-term uptick in XGN's stock price, given the significant improvement over the previous year's performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100